The BeiGene Satellite Symposium at the XIIIth International Workshop of the German CLL Study Group 2022 was chaired by Prof Barbara Eichhorst and joined by Prof Jennifer Brown. They discussed the current approaches and future direction of targeted therapy with BTK inhibitors for CLL patients.
Primary analysis of the ROSEWOOD trial – zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory (R/R) follicular lymphoma (FL).
Poster presented at WCLC 2022 describing the final analysis of RATIONALE-303, a Phase 3 trial comparing tislelizumab versus docetaxel in previously treated advanced NSCLC.
Poster presented at WCLC 2022 describing the preliminary results of PD-L1-positive, locally advanced or metastatic, non-squamous NSCLC cohort H from the Phase 1b SAFFRON-103 trial.
Poster presented at WCLC 2022 describing the preliminary results of PD-L1-positive, locally advanced or metastatic, squamous NSCLC cohort I from the Phase 1b SAFFRON-103 trial.
